Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianda PharmaceuticalsHKSE:00455 -12.60%24 Gross Margin % is 41.18% as of Dec. 2025, which is 26% below its 10-year median of 56.02. GuruFocus rates HKSE:00455 with a GF Score™ of 24/100 and a GF Value™ of HK$0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Tianda Pharmaceuticals ranks worse than 64.18% on this metric.
HKSE:00455's Gross Margin % is ranked worse than 64.18% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.51
vs HKSE:00455: 40.76
Tianda Pharmaceuticals had a gross margin of 41.18% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Tianda Pharmaceuticals was -9.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Tianda Pharmaceuticals had a gross margin of 41.18% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Tianda Pharmaceuticals Gross Margin % Related Terms
Tianda Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Tianda Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianda Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Tianda Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Tianda Pharmaceuticals (HKSE:00455) has a Gross Margin % of 41.18% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Tianda Pharmaceuticals and its competitors. This is 26% below median its historical median of 56.02. Over the past decade, Tianda Pharmaceuticals' Gross Margin % has ranged from 40.76 to 80.47. According to the industry distribution chart, Tianda Pharmaceuticals ranks #602 out of 938 companies in the Drug Manufacturers industry, placing it in the top 64.2%.
Is Tianda Pharmaceuticals' Gross Margin % too high?
Tianda Pharmaceuticals' current Gross Margin % of 41.18% is 26% below median its 10-year median of 56.02. Over the past 10 years, this metric has ranged from a low of 40.76 to a high of 80.47. The Drug Manufacturers industry median Gross Margin % is 48.51. Tianda Pharmaceuticals' value of 41.18% is 15.1% below this industry median. Based on the distribution chart, Tianda Pharmaceuticals ranks #602 out of 938 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianda Pharmaceuticals ranks #602 out of 938 companies for Gross Margin %. This places Tianda Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.51. Tianda Pharmaceuticals' value of 41.18% is 15.1% below this benchmark. Historically, Tianda Pharmaceuticals' own Gross Margin % has ranged from 40.76 to 80.47 over the past decade. While the company's 10-year median is 56.02 vs. the industry median of 48.51, Tianda Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.51, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianda Pharmaceuticals's current Gross Margin % of 41.18% is 15.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Tianda Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianda Pharmaceuticals's current Gross Margin % is 41.18%, which is 26% below median its own 10-year median of 56.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current Gross Margin % is 41.18%, which is 26% below median its 10-year median of 56.02 and 15.1% below the Drug Manufacturers industry median of 48.51. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current Gross Margin % is 41.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?
Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued.
The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13.
GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKSE:00455:
Gross Margin %: 41.18% (26% below median its 10-year median of 56.02)
GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
Industry Position: 15.1% below the Drug Manufacturers median (#602 of 938)
No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score
Get the complete analysis for HKSE:00455
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00455 has been successfully added to your 
